At last week’s BioStock Investor Meeting, femtech company Pharmiva was first out to present. CEO Anna Linton talked about Pharmiva’s product against bacterial vaginosis, Vernivia, which was launched in Sweden at the end of 2021. Linton also elaborated on the company’s expansion strategy and the current rights issue that will support a global launch.
See Pharmiva’s presentation here:
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.